Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ACRX

ACRX - AcelRx Pharmaceuticals Inc Stock Price, Fair Value and News

1.06USD+0.08 (+8.16%)Market Closed

Market Summary

ACRX
USD1.06+0.08
Market Closed
8.16%

ACRX Stock Price

View Fullscreen

ACRX RSI Chart

ACRX Valuation

Market Cap

16.7M

Price/Earnings (Trailing)

-1.17

Price/Sales (Trailing)

0.19

EV/EBITDA

-0.44

Price/Free Cashflow

-1.1

ACRX Price/Sales (Trailing)

ACRX Profitability

EBT Margin

-11.49%

Return on Equity

-86.93%

Return on Assets

-49.35%

Free Cashflow Yield

-90.82%

ACRX Fundamentals

ACRX Revenue

Revenue (TTM)

89.6M

ACRX Earnings

Earnings (TTM)

-14.2M

Earnings Growth (Yr)

51.5%

Earnings Growth (Qtr)

12.46%

Breaking Down ACRX Revenue

Last 7 days

1.0%

Last 30 days

-19.7%

Last 90 days

-14.8%

Trailing 12 Months

-19.0%

How does ACRX drawdown profile look like?

ACRX Financial Health

Current Ratio

5.97

ACRX Investor Care

Shares Dilution (1Y)

55.55%

Diluted EPS (TTM)

-1.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202389.6M000
202223.1M43.4M63.7M84.1M
20215.5M3.1M3.6M2.8M
20202.2M4.2M5.0M5.4M
20192.4M2.6M2.8M2.5M
20185.2M3.4M2.3M2.2M
201717.4M15.6M13.7M8.0M
201622.1M24.7M12.7M17.4M
20158.7M12.2M15.8M19.3M
201423.4M17.4M11.3M5.2M
20133.0M3.2M3.6M29.5M
20121.4M1.7M2.1M2.4M
20110001.1M

Tracking the Latest Insider Buys and Sells of AcelRx Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 13, 2023
angotti vincent j.
bought
7,268
0.7268
10,000
chief executive officer
Oct 10, 2023
bozilenko marina
acquired
-
-
581
-
Oct 10, 2023
afable richard
acquired
-
-
581
-
Oct 10, 2023
rosen howard b
acquired
-
-
581
-
Oct 10, 2023
broadfoot jill marie
acquired
-
-
581
-
Oct 10, 2023
adams adrian
acquired
-
-
581
-
Oct 10, 2023
wan mark a
acquired
-
-
581
-
Oct 10, 2023
hoffman stephen j
acquired
-
-
581
-
Sep 11, 2023
angotti vincent j.
bought
7,950
0.795
10,000
chief executive officer
Aug 25, 2023
palmer pamela p
sold
-8,104
1.089
-7,442
chief medical officer

1–10 of 50

Which funds bought or sold ACRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
reduced
-80.51
-35,000
13,000
-%
May 16, 2024
JANE STREET GROUP, LLC
added
29.47
7,315
16,297
-%
May 15, 2024
CITADEL ADVISORS LLC
added
37.6
20,400
42,375
-%
May 15, 2024
STATE STREET CORP
unchanged
-
6,543
22,847
-%
May 15, 2024
MORGAN STANLEY
reduced
-32.36
-548
9,963
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
sold off
-100
-16.00
-
-%
May 15, 2024
Rock Springs Capital Management LP
unchanged
-
93,356
325,954
0.01%
May 15, 2024
Tower Research Capital LLC (TRC)
added
6.03
2,724
8,330
-%
May 15, 2024
Nantahala Capital Management, LLC
reduced
-19.5
233,143
2,052,300
0.12%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
sold off
-100
-15,473
-
-%

1–10 of 37

Are Funds Buying or Selling ACRX?

Are funds buying ACRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ACRX
No. of Funds

Unveiling AcelRx Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
4.99%
890,346
SC 13G/A
Feb 13, 2024
lind global fund ii lp
4.2%
735,296
SC 13G/A
Jan 23, 2024
nantahala capital management, llc
11.8%
1,992,519
SC 13D
Aug 01, 2023
lind global fund ii lp
6.5%
1,102,944
SC 13G
Feb 14, 2023
armistice capital, llc
9.99%
864,328
SC 13G/A
Feb 15, 2022
armistice capital, llc
9.99%
12,314,479
SC 13G
Jan 27, 2022
bml investment partners, l.p.
0.0%
0
SC 13G/A
Jul 12, 2021
blackrock inc.
1.9%
2,266,040
SC 13G/A
Feb 10, 2021
bml investment partners, l.p.
5.3%
5,200,000
SC 13G/A
Jan 29, 2021
blackrock inc.
5.7%
5,640,946
SC 13G/A

Recent SEC filings of AcelRx Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
May 20, 2024
S-8
Employee Benefits Plan
May 14, 2024
8-K
Current Report
May 14, 2024
10-Q
Quarterly Report
Apr 29, 2024
DEFA14A
DEFA14A
Apr 29, 2024
DEF 14A
DEF 14A
Apr 29, 2024
ARS
ARS
Apr 19, 2024
8-K
Current Report
Mar 21, 2024
4
Insider Trading
Mar 15, 2024
4
Insider Trading
Mar 12, 2024
4
Insider Trading

Peers (Alternatives to AcelRx Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
350.0B
85.6B
-3.94% -10.00%
9.1
4.09
5.68% 202.39%
327.6B
61.4B
0.54% 19.05%
142.08
5.34
6.11% -82.30%
160.0B
29.5B
-4.21% 34.20%
42.52
5.42
12.76% -52.47%
156.6B
35.0B
-2.61% -29.78%
134.79
4.47
-26.40% -92.03%
79.1B
27.4B
-6.10% -18.51%
163.34
2.88
1.51% -91.32%
19.5B
16.0B
1.81% 133.24%
-39.52
1.22
7.23% 71.10%
MID-CAP
4.2B
1.7B
1.31% -21.88%
9.66
2.43
54.01% 364.56%
3.7B
4.6B
-9.61% -18.87%
-484.91
0.82
-0.06% 94.55%
2.3B
9.0B
-13.20% -15.57%
-4.97
0.25
10.01% -27.45%
2.0B
676.2M
-1.62% -15.25%
12.84
2.94
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-16.75% 6.10%
-3.83
1.81
24.65% 80.36%
22.8M
1.3M
-2.94% -47.62%
-3.08
17.54
-98.14% -104.71%
16.7M
89.6M
-19.67% -19.01%
-1.17
0.19
287.27% -129.41%
2.5M
21.5M
-5.26% -89.66%
-0.32
0.11
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

AcelRx Pharmaceuticals Inc News

Latest updates
FiercePharma5 months ago

AcelRx Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-100.0%-5,511,000--84,052,00042,027,0002,0001,862,000443,000511,000738,0001,368,0002,924,000386,000294,000608,000941,000627,000613,000377,000818,000
Costs and Expenses-20.5%4,237,0005,328,0005,886,0004,523,0009,955,0004,936,000-12,112,00010,495,00010,458,0009,653,0009,982,00010,405,0009,758,00016,234,00015,467,00014,142,00014,302,00012,583,00011,590,0009,705,0007,971,000
Operating Expenses-------------------11,590,0009,705,0007,971,000
  S&GA Expenses-34.5%2,804,0004,281,0005,227,0003,724,0003,960,0004,100,000-9,490,0008,640,0008,694,0007,644,0007,846,0007,598,0007,575,00013,311,00012,786,00010,936,00011,329,0009,976,0007,648,0005,188,0003,944,000
  R&D Expenses36.9%1,433,0001,047,000612,000799,0001,094,000836,000-674,0001,416,000724,000969,000836,000956,000813,0001,412,0001,063,0001,058,0001,163,0001,377,0002,704,0003,642,0003,278,000
EBITDA Margin-112.8%-0.110.900.961.081.52-0.57-4.59-8.89-9.65------------
Interest Expenses-100.0%-119,000188,000245,000293,000390,000369,000538,000614,000672,000754,000824,000872,000855,000831,000828,000500,000376,000459,000529,000586,000
Income Taxes----1,00011,0003,000---5,000---4,000---3,000---2,000
Earnings Before Taxes---3,885,000-6,739,00070,666,000-10,030,000-8,375,000-9,846,000--8,918,000-8,930,000-6,602,000--14,423,000-12,731,000-12,409,000--12,558,000-12,458,000-10,539,000
EBT Margin-113.2%-0.110.870.931.031.44-0.74-6.07-10.15-11.21------------
Net Income51.5%-3,954,000-8,152,000-7,484,000-6,750,00070,663,000-8,674,000-7,917,000-8,375,000-9,851,000-8,956,000-8,918,000-8,930,000-6,606,000-15,925,000-14,423,000-12,731,000-12,412,000-13,674,000-12,558,000-12,458,000-
Net Income Margin-129.4%-0.160.540.570.741.05-1.51-12.46-10.16-11.98------------
Free Cashflow46.1%-2,883,000-5,350,000-5,461,000-5,396,000-8,815,000-9,023,000-8,032,000-4,127,000-9,938,000------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets41.1%29.0020.0023.0018.0026.0047.0048.0056.0072.0078.0072.0080.0087.0066.0066.0067.0077.0091.00105115113
  Current Assets72.4%20.0012.0014.009.0017.0025.0025.0032.0043.0050.0052.0059.0071.0047.0048.0049.0058.0072.0086.0097.0095.00
    Cash Equivalents111.9%12.006.0013.007.0013.0015.0013.0015.0022.008.008.0021.0034.0022.0020.0022.0024.0015.0022.0065.0073.00
  Inventory------1.001.001.001.001.002.001.001.002.002.003.003.003.003.003.002.00
  Net PPE-------11.0011.0016.005.0016.0016.0016.0016.0014.0014.0015.0015.0014.0013.0012.00
Liabilities97.7%12.006.005.007.0012.0026.0021.0023.00110114115116115122124128133133133134121
  Current Liabilities-25.9%3.005.004.004.009.0014.0016.0018.0017.0019.0017.0015.0016.0018.0017.0016.0016.0014.0011.008.0019.00
  Long Term Debt---------3.005.007.009.0011.0013.0015.0017.0019.0021.0022.0024.00-
    LT Debt, Current-----3.005.008.0010.009.008.009.009.009.009.009.009.007.005.002.00-10.00
    LT Debt, Non Current---------3.005.007.009.0011.0013.0015.0017.0019.0021.0022.0024.00-
Shareholder's Equity15.8%16.0014.0018.0010.0014.0022.0027.0033.00-------------
  Retained Earnings-0.9%-448-444-439-438-433-425-418-411-482-473-465-457-447-438-429-420-414-398-383-370-358
  Additional Paid-In Capital1.3%464458458449448448446445444438423421420383372360359357355352351
Shares Outstanding0.2%17.0017.0017.0011.0011.008.007.007.007.007.006.006.00---------
Float----12.00---36.00---161---95.00---197-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations27.0%-2,883-3,949-2,960-5,333-5,250-5,413-5,238-8,746-8,934-8,004-3,943-8,347-9,708-6,327-8,124-9,690-14,364-14,155-11,466-12,319-13,240
  Share Based Compensation-2.9%3023113784715696527017537831,1271,2211,1721,0891,0841,1041,0901,1461,2781,3261,3461,107
Cashflow From Investing25.2%-2,730-3,651-2,7234002,6604,4429,17220,176-4,439-6,6522,393-17,4255,775-1,2146,92822,6506,889-33,206-10,617371
Cashflow From Financing17767.6%12,014-68.008,939-3,333-2,0725,296-1,637-2,083-2,08311,835-2,461-2,08234,2227,8537,5226659161.001,55014,695-1,794
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ACRX Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating Costs and Expenses [Abstract]  
Research and development$ 1,433$ 1,047
Selling, general and administrative2,8044,281
Total operating costs and expenses4,2375,328
Nonoperating Income (Expense) [Abstract]  
Interest expense0(119)
Interest income and other income, net220200
Gain on sale of future payments1,2460
Change in fair value of warrant liability(1,002)5,311
Non-cash interest expense on liability related to sale of future payments(181)0
Total other income (expense), net2835,392
Net (loss) income from continuing operations(3,954)64
Net loss from discontinued operations– See Note 30(8,216)
Net loss$ (3,954)$ (8,152)
Basic and diluted, continuing operations (in dollars per share)$ (0.16)$ 0
Basic and diluted, discontinued operations (in dollars per share)0(0.75)
Basic and diluted loss per share (in dollars per share)$ (0.16)$ (0.75)
Shares used in computing net loss per share of common stock, basic and diluted – See Note 10 (in shares)24,721,96410,893,954
Product [Member]  
Operating Costs and Expenses [Abstract]  
Loss from operations$ (4,237)$ (5,328)

ACRX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
[1]
Assets, Current [Abstract]  
Cash and cash equivalents$ 12,122$ 5,721
Short-term investments6,4623,660
Prepaid expenses and other current assets1,3692,195
Total current assets19,95311,576
In-process research and development asset8,8198,819
Total Assets28,77220,395
Current Liabilities:  
Accounts payable1,2741,336
Accrued and other liabilities1,3402,445
Liabilities of discontinued operations, current portion730731
Total current liabilities3,3444,512
Warrant liability2,7801,778
Liability related to the sale of future payments6,3140
Total Liabilities12,4386,290
Commitments and Contingencies 
Common stock, $0.001 par value—200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 16,992,726 and 16,952,219 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively1717
Additional paid-in capital464,497458,314
Accumulated deficit(448,180)(444,226)
Total Stockholders’ Equity16,33414,105
Total Liabilities and Stockholders’ Equity$ 28,772$ 20,395
[1]The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
ACRX
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.
 CEO
 WEBSITEacelrx.com
 INDUSTRYPharmaceuticals
 EMPLOYEES19

AcelRx Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for AcelRx Pharmaceuticals Inc? What does ACRX stand for in stocks?

ACRX is the stock ticker symbol of AcelRx Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AcelRx Pharmaceuticals Inc (ACRX)?

As of Thu Jun 13 2024, market cap of AcelRx Pharmaceuticals Inc is 16.65 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACRX stock?

You can check ACRX's fair value in chart for subscribers.

What is the fair value of ACRX stock?

You can check ACRX's fair value in chart for subscribers. The fair value of AcelRx Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AcelRx Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AcelRx Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ACRX is over valued or under valued. Whether AcelRx Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact AcelRx Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACRX.

What is AcelRx Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, ACRX's PE ratio (Price to Earnings) is -1.17 and Price to Sales (PS) ratio is 0.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AcelRx Pharmaceuticals Inc's stock?

In the past 10 years, AcelRx Pharmaceuticals Inc has provided -0.21 (multiply by 100 for percentage) rate of return.